Edgestream Partners L.P. Buys New Shares in Integer Holdings Co. (NYSE:ITGR)

Edgestream Partners L.P. purchased a new position in Integer Holdings Co. (NYSE:ITGR) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor purchased 22,264 shares of the medical equipment provider’s stock, valued at approximately $2,894,000.

Several other hedge funds have also bought and sold shares of ITGR. Price T Rowe Associates Inc. MD lifted its stake in Integer by 6.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,031 shares of the medical equipment provider’s stock worth $2,221,000 after purchasing an additional 1,219 shares in the last quarter. Virtu Financial LLC purchased a new stake in Integer in the 1st quarter worth $298,000. GAMMA Investing LLC lifted its stake in Integer by 60.9% in the 2nd quarter. GAMMA Investing LLC now owns 375 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 142 shares in the last quarter. OLD National Bancorp IN purchased a new stake in Integer in the 2nd quarter worth $248,000. Finally, QRG Capital Management Inc. lifted its stake in Integer by 6.0% in the 2nd quarter. QRG Capital Management Inc. now owns 33,251 shares of the medical equipment provider’s stock worth $3,850,000 after purchasing an additional 1,883 shares in the last quarter. Hedge funds and other institutional investors own 99.29% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on ITGR shares. Truist Financial decreased their price target on shares of Integer from $150.00 to $147.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. Piper Sandler restated an “overweight” rating and issued a $140.00 target price (up from $125.00) on shares of Integer in a report on Friday, October 25th. Bank of America boosted their target price on shares of Integer from $135.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, October 1st. KeyCorp boosted their target price on shares of Integer from $139.00 to $144.00 and gave the stock an “overweight” rating in a report on Tuesday, October 15th. Finally, Citigroup boosted their target price on shares of Integer from $124.00 to $130.00 and gave the stock a “neutral” rating in a report on Tuesday, October 1st. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Integer currently has a consensus rating of “Moderate Buy” and a consensus price target of $139.75.

Integer Stock Performance

Shares of NYSE:ITGR opened at $140.50 on Monday. The company has a market capitalization of $4.71 billion, a price-to-earnings ratio of 43.36, a PEG ratio of 2.01 and a beta of 1.09. Integer Holdings Co. has a 12 month low of $84.75 and a 12 month high of $142.00. The firm’s 50-day moving average is $131.38 and its 200 day moving average is $124.50. The company has a current ratio of 3.28, a quick ratio of 2.09 and a debt-to-equity ratio of 0.67.

Integer (NYSE:ITGR) last issued its quarterly earnings results on Thursday, October 24th. The medical equipment provider reported $1.43 EPS for the quarter, beating the consensus estimate of $1.36 by $0.07. The company had revenue of $431.42 million for the quarter, compared to the consensus estimate of $440.59 million. Integer had a net margin of 6.70% and a return on equity of 11.63%. The firm’s revenue was up 8.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.27 EPS. Research analysts predict that Integer Holdings Co. will post 5.33 EPS for the current year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.